

Substitute for form 1449A/PTO

**Complete if Known**

*(use as many sheets as necessary)*

Sheet 1 of 3

Application Number	09/671,773
Filing Date	September 27, 2000
First Named Inventor	Clark Pan
Group Art Unit	<del>1641</del> 1631
Examiner Name	<del>Kimberly White</del> Morel
Attorney Docket Number	MSE-7272

APR 10 2002  
TECH CENTER 1600/2900

[illegible][illegible]

Examiner  
Signature

Date	
Considered	

1/3/10 3

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

Application Number	09/671,773
Filing Date	September 27, 2000
First Named Inventor	Clark Pan
Group Art Unit	1641-1631
Examiner Name	Kimberly White Mora
Attorney Docket Number	MSB-7272

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
msj	G1	GOURLET et al., Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes. European Journal of Pharmacology, vol. 348, no. 1, 1 May 1998 (1998-05-01), pages 95-99.	
msj	HI	INAGAKI et al., Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proceedings of the National Academy of Sciences of the United States, vol. 91, no. 7, 1994, pages 2679-2683.	
msj	II	GOURLET, et al., C-Terminally Shortened Pituitary Adenylate Cyclase-Activating Peptides (PACAP) Discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 Recombinant Receptors. Regulatory Peptides, NL, Elsevier Science BV, vol. 62, no. 2/03, 1996, pages 125-130.	
msj	J1	GOURLET, et al, Analogues of VIP, helodermin and PACAP discriminate between rat and human VIP1 and VIP2 receptors. Annals of the New York Academy of Sciences, vol. 865, 11 December 1998 (1998-12-11), pages 247-252.	
msj	K1	DICKINSON et al., VIP and PACAP: very important in pain?, Trends in Pharmacological Sciences, GB, Elsevier Trends Journal, Cambridge, vol. 20, no. 8, 1 August 1999 (1999-08-01), pages 324-329.	
msj	L1	HARMAR, et al., International union of pharmacology, XVIII, Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide, Pharmacological Reviews, vol. 50, no. 2, June 1998 (1998-06) pages 265-270.	
msj	M1	GOURLET et al., The long acting vasoactive intestinal polypeptide agonist R025-1553IS highly selective of the VIP2 Receptor Subclass, Peptides, US, Elmsford, vol. 18, no. 3, 1997, pages 403-408.	
msj	N1	ROBBERECHT et al., Interet Des Recepteurs Recombinants Dans L'Elaboration D'Agonistes et D'Antagonistes Des Recepteurs Du VIP Et Du PACAP. Interest of recombinant receptors for the testing of pharmacologie de Belgique, (1996-05-01), pages 165-169.	
msj	O1	NOKIHARA et al., Receptor recognition of PACAP and VIP examined by binding studies <del>AMP</del> production and biological actions both in vivo and in vitro by means of selective residue substitution, Edinburgh, Sept 8 - 13, 1996, West Midlands: Mayflower Scientific, GB, vol. SYMP. 24, 1996, pages 63-66.	
msj	P1	GOURLET et al., Addition of the (28-38) peptide sequence of PACAP to the VIP sequence modifies peptide selectivity and efficacy, International Journal of peptide and protein research, DK, Munksgaard, Copenhagen, vol. 48, no. 4 1 October 1996 (1996-10-01), pages 391-396.	
msj	Q1	POHL, Molecular cloning of the helodermin and exedin-4 cDNAs in the lizard: relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues, Journal of Biological Chemistry, vol. 273, no. 16, 17 April 1998 (1998-04-17), pages 9778-9784.	

Examiner  
Signature

MA Mora


Date  
Considered

1/31/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



APR 10 2002

RECEIVED

Substitute for form 1449B/PTO

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Application Number 09/671,773  
 Filing Date September 27, 2000  
 First Named Inventor Clark Pan  
 Group Art Unit 1641 1631  
 Examiner Name Kimberly White Moran  
 Attorney Docket Number MSB-7272

TECH CENTER 600/2200

APR 10 2002

RECEIVED

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
msy	R1	BOLIN, et al, Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma, Biopolymers 1995;37(2):57-66.
msy	S1	YOKOTA, et al, PACAP stimulates glucose output from the perfused rat liver. Peptides 16:55-60, 1995.
msy	T1	STRAUB et al., A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide, J Biol Chem 271: 1660-1668, 1996.
msy	U1	SEKIGUCHI, et al., Glycogenolytic activity of pituitary adenylate cyclase activating polypeptide (PACAP) in vivo and in vitro Life Sci vol. 55, No. 15, pp. 1219-1228, 1994.
msy	V1	FILIPSSON, et al, PACAP and PACAP receptors in insulin producing tissues: localization and effects. Regul Pept 74: 167-175, 1998.
msy	W1	PASCAL et al., Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1, and VPAC2 Receptors and Development of a highly selective of a highly selective VPAC1 receptor agonist. The Journal of Biological Chemistry vol 275, no. 31, Issue of August 4, pp 24003-24012, (2000).
msy	X1	XIA et al., Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor, J Pharmacol Exp Ther. 1997 May; 281(2): 629-33.
msy	Y1	YADA et al., Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. J Biol Chem vol. 269, No. 2, Issue of January 14, pp 1290-1293, 1994.
msy	Z1	VANDERMEERS et al., Antagonistic properties are shifted back to agonist properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 Cell membranes. (Eur. J. Biochem. 208, 815-819 (1992).
msy	G2	KOMATSU et al., Augmentation of insulin release by glucose in the absence of extracellular ca2+ (Diabetes, vol. 46, December 1997), pp. 1928-1938.

Examiner Signature

Ma Moran

Date Considered

11/31/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.